Compare Crispr Therapeutics AG (CRSP) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SMX Security Matters plc — how do they compare? Crispr Therapeutics AG trades at $50.88 (market cap $4.97B), while SMX Security Matters plc trades at $20.31 (market cap $17.11M). The key difference: Crispr Therapeutics AG is far larger — about 290.5× SMX Security Matters plc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| CRSP | SMX | |
|---|---|---|
Market Cap | $4.97B | $17.11M |
Sector | Health | Technology |
52-Week High | $76.78 | $295.56K |
52-Week Low | $44.34 | $12.87 |
Enterprise Value | $3.32B | $14.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SMX trades at $16.21, up 3.58% today, amid neutral technical signals and recent reverse stock splits. The company is positioning itself in the recycling technology space with its Circularity-as-a-Service platform, targeting demand from new state recycling mandates. However, financial metrics show significant challenges with negative ROE of -2,216.26% and ROA of -398.22%, indicating substantial profitability concerns despite a reasonable P/B ratio of 1.93.
The outlook remains speculative with potential upside from regulatory tailwinds in recycling verification technology, but high execution risk given current negative profitability. Investors face substantial dilution risk from recent reverse splits and need to monitor the company's ability to convert regulatory opportunities into sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
